YOLFTbeta
BRAIN Biotech AG

BRAIN Biotech AG

BNN · XETRA · Basic Materials / Specialty Chemicals

2.56EUR-0.01 (-0.39%)

Price History

Full chart

Market Stats

Previous Close2.57
Open2.57
Day Range2.54 – 2.58
52-Week Range2.05 – 3.74
Volume1.98K
Market Cap63.14M
P/E (TTM)0.00
Forward P/E285.71
EPS-0.64
Dividend Yield0.00%
Beta0.62
50-Day Avg2.79
200-Day Avg2.68

About

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Company Details

  • SectorBasic Materials
  • IndustrySpecialty Chemicals
  • CEOMr. Adriaan Moelker
  • Employees280
  • HeadquartersDarmstädter Strasse 34-36, Zwingenberg, Germany, 64673, Germany
  • Websitehttps://www.brain-biotech.com

Leadership

  • Mr. Adriaan MoelkerChairman of the Management Board & CEO
  • Mr. Ulrich PutschCo-Founder
  • Mr. Michael SchneidersCFO & Member of Management Board · b. 1970
  • Dr. Ute DechertVice President of Human Resources & Processes · b. 1961
  • Dr. Jurgen EckConsultant · b. 1962
  • Dr. Martin LangerMD & Executive VP · b. 1965
  • Dr. Alexander PelzerVP and Head of Research & Development - Zwingenberg · b. 1986
  • Mr. Robbert Michael HoekstraHead of Group Finance · b. 1978
  • Mr. Johan Jansen-StorbackaExecutive VP of BRAIN Biocatalysts enzyme products business

Financials

Income Statement

Currency: EUR2012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue7.48M10.13M12.99M21.13M22.79M24.11M27.05M38.56M38.23M38.39M49.51M55.34M54.63M49.62M
Growth (%)-+35.56%+28.15%+62.71%+7.84%+5.77%+12.22%+42.55%-0.87%+0.43%+28.97%+11.77%-1.27%-9.17%
Cost of Revenue4.02M4.32M4.97M10.98M11.42M11.36M13.66M17.45M17.02M40.34M48.08M51.87M54.23M47.62M
Gross Profit3.46M5.82M8.01M10.15M11.37M12.75M13.39M21.11M21.20M-1.95M1.43M3.47M401.00K2.01M
Gross Margin46.23%57.40%61.70%48.02%49.89%52.88%49.50%54.76%55.46%-5.09%2.88%6.27%0.73%4.04%
Operating Expense9.13M10.21M12.96M14.72M25.18M22.12M23.43M26.77M30.07M4.59M8.95M10.18M9.25M10.51M
Operating Income-5.67M-4.39M-4.94M-4.57M-13.81M-9.37M-10.04M-5.65M-8.87M-6.55M-7.53M-6.71M-8.85M-8.51M
Operating Margin-75.84%-43.30%-38.07%-21.64%-60.60%-38.89%-37.12%-14.66%-23.21%-17.06%-15.20%-12.14%-16.20%-17.15%
EBITDA-5.01M-3.72M-3.94M-3.45M-12.63M-7.59M-5.11M-5.71M-2.78M2.01M-1.30M-1.98M-4.23M-4.17M
EBITDA Margin-67.00%-36.68%-30.33%-16.34%-55.44%-31.48%-18.91%-14.81%-7.26%5.25%-2.62%-3.57%-7.74%-8.40%
Net Income-5.54M-4.10M-5.04M-5.71M-14.69M-9.61M-8.28M-10.49M-9.68M-4.97M-6.59M-8.28M-11.13M-11.74M
Net Income Margin-74.06%-40.41%-38.84%-27.04%-64.46%-39.85%-30.59%-27.22%-25.33%-12.95%-13.31%-14.96%-20.37%-23.66%
R&D4.84M6.08M5.80M6.18M5.85M8.07M7.58M7.82M5.79M5.38M4.87M4.98M-3.88M
R&D as % of Total Revenue64.74%60.04%44.65%29.26%25.66%33.47%28.01%20.28%15.14%14.02%9.84%9.00%-7.83%
Interest Expense--0581.17K1.05M313.00K349.00K686.00K845.00K553.00K572.00K942.00K1.94M2.21M
Interest Expense % of Total Revenue--0.00%2.75%4.60%1.30%1.29%1.78%2.21%1.44%1.16%1.70%3.55%4.44%

Balance Sheet

Currency: EUR2012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets19.71M25.10M25.07M30.41M47.51M68.50M74.46M66.12M72.15M77.74M77.99M70.94M88.74M66.34M
Total Liabilities7.59M7.51M11.22M24.65M20.59M21.14M43.83M49.03M46.01M35.91M43.74M47.92M74.85M64.50M
Total Equity11.41M17.30M12.26M5.45M26.68M47.18M25.75M12.23M20.79M38.78M29.64M21.77M12.62M1.84M
Cash2.53M9.26M4.46M3.18M8.26M38.95M25.54M15.16M18.94M24.55M8.44M5.35M27.17M6.19M
Total Debt-3.53M4.79M16.36M9.69M9.70M27.80M28.38M30.60M11.70M11.07M25.32M29.82M24.03M
Net Debt-2.53M-5.73M328.40K13.18M1.43M-29.26M2.26M13.22M11.65M-21.90M-5.41M-693.00K2.65M17.84M

Cash Flow

Currency: EUR2012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-5.89M-4.85M-3.90M-4.11M-8.68M-5.76M-5.42M-3.38M-4.77M-3.91M-1.49M-4.22M-3.58M-9.23M
Investing Cash Flow4.92M1.52M-1.52M-539.12K-11.23M8.79M-12.62M-6.74M-4.47M-2.18M-12.69M562.00K-1.69M-1.56M
Financing Cash Flow338.28K10.06M621.03K3.44M24.99M27.66M4.66M-276.00K13.09M11.57M-1.97M459.00K26.99M-10.14M
Capital Expenditure335.89K585.69K494.82K591.85K1.23M1.08M1.51M6.64M2.86M1.26M6.08M2.64M1.73M1.53M
Free Cash Flow-6.22M-5.43M-4.40M-4.71M-9.91M-6.83M-6.93M-10.02M-7.63M-5.17M-7.57M-6.86M-5.31M-10.76M
FCF to OCF105.71%112.08%112.68%114.39%114.17%118.73%127.93%296.36%159.97%132.31%509.56%162.54%148.26%116.58%

Earnings

Report DateMar 31, 2016Aug 31, 2016Nov 30, 2016Jan 16, 2017May 31, 2017Aug 30, 2017Nov 29, 2017Feb 28, 2018May 30, 2018Aug 31, 2018May 29, 2019Feb 24, 2026May 26, 2026Jun 30, 2026
EPS Estimate---0.10-0.10-----0.040.10----
EPS Actual-0.25-0.15-0.15-0.39-0.08-0.10-0.12-0.10-0.13-0.12-0.16-0.13-0.16-0.16
Surprise---50.00%-290.00%-----225.00%-220.00%----
Timing---After-hours---Pre-marketPre-marketAfter-hours-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap63.14M
Enterprise Value61.49M
Trailing P/E0.00
Forward P/E285.71
PEG Ratio0.00
Price / Sales1.37
Price / Book9.62
EPS-0.64
Book Value-0.326
Revenue (TTM)46.08M
Gross Profit (TTM)26.42M
EBITDA-5.14M
Profit Margin-30.33%
Operating Margin-19.97%
Return on Equity-663.98%
Return on Assets-8.01%
Shares Outstanding21.85M
Shares Float9.09M
Beta0.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%